Physician

Aamra Sheikh, M.D.

According to 2025 Medicare claims, Aamra Sheikh, M.D. (NPI: 1376745125) practices internal medicine in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is PERMANENTE MEDICAL GROUP INC (NPI: 1639252604; TIN: 954402957) and primary practice location at 94063-2037.

Sheikh's data goes back to 2015 and runs through 2024. Part D data shows 4,174 prescription claims across 607 beneficiaries totaling $142,859 in drug costs, led by Spiriva Respimat (Tiotropium Bromide). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

No connected Part B records

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	498	4,341	$196,697
2016	477	3,711	$159,244
2017	410	3,452	$148,327
2018	480	3,564	$166,381
2019	547	3,699	$157,030
2020	407	3,463	$137,861
2021	534	4,138	$169,121
2022	710	4,529	$181,705
2023	813	4,584	$170,009
2024	607	4,174	$142,859

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

No connected Part B code-level records for 2024.

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Spiriva Respimat	Tiotropium Bromide	23	1,650	$16,637
Pradaxa	Dabigatran Etexilate Mesylate	35	3,030	$10,078
Jardiance	Empagliflozin	15	1,480	$9,088
Breyna	Budesonide/Formoterol Fumarate	30	1,185	$7,789
Wixela Inhub	Fluticasone Propion/Salmeterol	28	1,980	$6,923

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Aamra Sheikh, M.D.?

Tedicare shows public-source Medicare data for Aamra Sheikh, M.D. (NPI 1376745125), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aamra Sheikh, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aamra Sheikh, M.D.?

Aamra Sheikh, M.D. is linked to PERMANENTE MEDICAL GROUP INC (billing NPI 1639252604) in the available physician profile data.

Does Aamra Sheikh, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.